Model Prescription for Diabetes Mellitus with Cardiovascular Risk
For patients with type 2 diabetes and established cardiovascular disease, prescribe an SGLT2 inhibitor (empagliflozin 10 mg daily or canagliflozin 100 mg daily) AND a GLP-1 receptor agonist (liraglutide 1.8 mg daily subcutaneous) on top of metformin and standard cardiovascular therapies, regardless of current HbA1c level. 1, 2
Core Prescription Components
Glucose-Lowering Medications (in order of priority):
1. Metformin (if eGFR ≥30 mL/min/1.73 m²)
- Start: 500-850 mg daily with meals
- Target: 1000 mg twice daily or 2000 mg daily
- First-line therapy unless contraindicated 1, 3
2. SGLT2 Inhibitor (Class I recommendation)
- Empagliflozin 10 mg PO daily (preferred based on strongest evidence for CV death reduction) 1
- No uptitration needed for CV benefit
- Requires eGFR ≥45 mL/min/1.73 m² to initiate
- Continue if eGFR drops to 30-45 (CV benefit persists)
- Alternative: Canagliflozin 100 mg PO daily (also FDA-approved for CV death reduction) 1
- Do not exceed 100 mg if eGFR 45-59 mL/min/1.73 m²
3. GLP-1 Receptor Agonist (Class I recommendation)
- Liraglutide (most convincing CV benefit data) 1
- Start: 0.6 mg subcutaneous daily
- Titrate weekly: 1.2 mg daily → 1.8 mg daily (goal dose for CV benefit)
- Alternative: Semaglutide or dulaglutide 2, 4
Cardiovascular Medications (mandatory):
4. Statin Therapy (high-intensity)
- Atorvastatin 40-80 mg daily OR Rosuvastatin 20-40 mg daily
- Target LDL <70 mg/dL (consider <55 mg/dL if very high risk) 3
5. ACE Inhibitor or ARB
- Lisinopril 10-40 mg daily OR Losartan 50-100 mg daily
- Essential if hypertension or albuminuria present 3, 5
6. Antiplatelet Therapy
- Aspirin 81 mg daily (if established ASCVD) 3
7. Beta-Blocker (if prior MI or heart failure)
- Carvedilol preferred (better glycemic effects than metoprolol) 5
- Carvedilol 6.25-25 mg twice daily
Critical Monitoring and Dose Adjustments
When Starting SGLT2 Inhibitors:
- Reduce insulin dose by 20% if on insulin (avoid >20% reduction initially) 1
- Reduce sulfonylurea dose by 50% or discontinue if on minimal dose 1
- Check eGFR within 2-4 weeks of initiation 1
- Counsel on genital hygiene (mycotic infection risk) 1
- Warn about euglycemic DKA symptoms: nausea, vomiting, abdominal pain, weakness 1
- Monitor for volume depletion, especially if elderly or on diuretics 1
When Starting GLP-1 RA:
- Titrate slowly to minimize nausea 1
- No hypoglycemia risk if not on insulin/sulfonylureas
- If on insulin/sulfonylureas: reduce doses as above
Special Populations
If Heart Failure Present:
- SGLT2 inhibitor is MANDATORY (empagliflozin, dapagliflozin, or canagliflozin) 6, 4
- Reduces HF hospitalization by 32-35% 1, 6
- Avoid thiazolidinediones (pioglitazone) - increases HF risk 6
- Avoid saxagliptin - increases HF hospitalization 6
If Chronic Kidney Disease (eGFR 30-60):
- Continue SGLT2 inhibitor (CV benefit persists) 1, 2
- Add finerenone if albuminuria present 2
- Metformin safe if eGFR ≥30 5
If eGFR <30 mL/min/1.73 m²:
- Stop SGLT2 inhibitor (not effective for glucose lowering, though trials ongoing for CV benefit) 1
- Continue GLP-1 RA (safe to eGFR >15) 5
- Insulin may be required; reduce doses as renal function declines 5
Common Pitfalls to Avoid
Do NOT wait for HbA1c >7% to start SGLT2i/GLP-1 RA in patients with established CVD - CV benefit is independent of glucose control 1, 2
Do NOT require sulfonylurea failure before adding SGLT2i/GLP-1 RA - this delays proven CV benefit 7
Do NOT use both SGLT2i and GLP-1 RA at maximum doses initially - start SGLT2i at lowest dose (10 mg empagliflozin), titrate GLP-1 RA slowly 1
Do NOT combine ACE inhibitor + ARB - increases hyperkalemia risk without benefit 5
Do NOT use canagliflozin if high amputation risk (peripheral vascular disease, prior amputation, neuropathy) - increased amputation risk observed 1
Combination Therapy Rationale
Both SGLT2 inhibitor AND GLP-1 RA can be used together - their mechanisms are complementary, and combination therapy is reasonable for maximal CV risk reduction, though not specifically studied for this indication 1. SGLT2 inhibitors primarily reduce heart failure and renal events, while GLP-1 RAs primarily reduce atherosclerotic events (MI, stroke) 1, 4.
This prescription prioritizes mortality and morbidity reduction over glucose control alone, reflecting the paradigm shift in diabetes management toward organ protection 1, 2.